Technology

Albubody™

Antibody fragment(scFv)

  • PTMS, 16 disulfides
  • 2 disulfides
  • 150 kDa
  • 25 kDa
  • Bivalent
  • Ｍonovalent
  • Fc region
  • No Fc region
  • Short serum half-life
  • Very short serum half-life
·Site-specific conjugation
·Retained the original structure and target affinity
·High cancer tissue permeability due to small size and albumin itself
·Minimized immunogenicity and side effect attributed to the Fc region
·Extended drug half-life through serum albumin binding
·Economic manufacturing cost

Albubody™

Albubody™ is a Next-generation technology platform that combines the advantage of scFv fragments while overcoming the short half-life of scFv by binding to serum albumin.

KOR